MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-24-2026
Danaher Corporation General and Administrative Expenses 2011-2026 | DHR
General and Administrative Expenses — these are a part of a company's operating expenses that are not directly related to the production of goods or the provision of services but are necessary for the overall functioning of the business.What these expenses include
- Salaries of administrative staff (executives, HR, accountants, legal personnel)
- Office rent and utilities
- Office equipment and IT infrastructure
- Professional services (auditors, lawyers, consultants)
- Insurance
- General administrative travel and representation expenses
- Cost control
A high level of such expenses may indicate inefficient management or an overly complex structure - Profitability
Reducing administrative expenses while maintaining stable revenue increases operating profit - Comparative analysis
Investors can compare this metric as a percentage of revenue among companies in the same industry - Business flexibility
Companies with a flexible and controlled expense structure are more resilient to revenue declines
Annual General and Administrative Expenses Danaher Corporation
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 8.24 B | 7.76 B | 7.33 B | 7.12 B | 6.82 B | 6.9 B | 5.59 B | 6.47 B | 6.04 B | 5.61 B | 6.05 B | 5.7 B | 5.43 B | 5.18 B | 4.61 B |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 8.24 B | 4.61 B | 6.32 B |
Quarterly General and Administrative Expenses Danaher Corporation
| 2025-Q1 | 2024-Q4 | 2024-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.86 B | - | 1.81 B | - | - | 2.08 B | 2.09 B | - | 2.06 B | 1.97 B | 1.88 B | - | 1.8 B | 1.68 B | 1.46 B | - | 1.38 B | 1.39 B | 1.37 B | - | 1.56 B | 1.64 B | 1.6 B | - | 1.5 B | 1.52 B | 1.45 B | - | 1.35 B | 1.43 B | 1.33 B | - | 1.2 B | 1.4 B | 1.41 B | - | 1.3 B | 1.39 B | 1.35 B | - | 1.3 B | 1.34 B | 1.3 B | - | 1.25 B | 1.28 B | 1.24 B | - | 1.27 B | 1.09 B | 963 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 2.09 B | 963 M | 1.49 B |
General and Administrative Expenses of other stocks in the Diagnostics research industry
| Issuer | General and Administrative Expenses | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Agilent Technologies
A
|
1.62 B | $ 119.04 | - | $ 36.2 B |  USA |
 |
Anixa Biosciences
ANIX
|
6.63 M | $ 2.83 | - | $ 91.8 K | USA |
 |
Centogene N.V.
CNTG
|
46.7 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Burning Rock Biotech Limited
BNR
|
490 M | $ 23.54 | - | $ 247 M |  China |
 |
Aspira Women's Health
AWH
|
16.2 M | - | -6.19 % | $ 10.5 M | USA |
 |
Castle Biosciences
CSTL
|
200 M | $ 27.57 | - | $ 766 M | USA |
 |
Celcuity
CELC
|
9.06 M | $ 107.4 | - | $ 4.24 B | USA |
|
Akumin
AKU
|
2.08 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Fulgent Genetics
FLGT
|
88.1 M | $ 13.79 | - | $ 417 M | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
22.3 M | - | - | $ 562 M |  Britain |
 |
Heska Corporation
HSKA
|
64.1 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
15.8 M | - | -20.0 % | $ 1.06 M | USA |
 |
Charles River Laboratories International
CRL
|
743 M | $ 175.69 | - | $ 8.71 B | USA |
 |
IDEXX Laboratories
IDXX
|
405 M | $ 635.54 | - | $ 51.1 B | USA |
 |
Accelerate Diagnostics
AXDX
|
39.2 M | - | -61.36 % | $ 2.46 M | USA |
 |
Illumina
ILMN
|
1.09 B | $ 129.56 | - | $ 20.6 B | USA |
 |
Global Cord Blood Corporation
CO
|
187 M | - | - | $ 399 M | China |
 |
Fluidigm Corporation
FLDM
|
97.9 M | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
3.83 M | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
126 M | - | 0.12 % | $ 80.1 M | China |
 |
PRA Health Sciences, Inc.
PRAH
|
453 M | - | - | $ 10.7 B | USA |
 |
Laboratory Corporation of America Holdings
LH
|
2.22 B | $ 282.99 | - | $ 23.5 B | USA |
 |
Lantheus Holdings
LNTH
|
275 M | $ 78.84 | - | $ 5.32 B | USA |
 |
Motus GI Holdings
MOTS
|
6.58 M | - | -34.28 % | $ 263 K |  Israel |
|
Biodesix
BDSX
|
80.5 M | $ 15.5 | - | $ 2.01 B | USA |
 |
Biocept
BIOC
|
16.1 M | - | -13.05 % | $ 7.29 M | USA |
 |
Mettler-Toledo International
MTD
|
998 M | $ 1 316.71 | - | $ 27.1 B |  Schweiz |
 |
Myriad Genetics
MYGN
|
257 M | $ 5.29 | - | $ 490 M | USA |
 |
Invitae Corporation
NVTA
|
192 M | - | - | $ 21.2 M | USA |
 |
NeoGenomics
NEO
|
273 M | $ 9.54 | - | $ 1.22 B | USA |
 |
BioNano Genomics
BNGO
|
51.9 M | $ 1.12 | - | $ 1.42 M | USA |
 |
Quest Diagnostics Incorporated
DGX
|
1.97 B | $ 208.36 | - | $ 23.1 B | USA |
 |
National Research Corporation
NRC
|
46.6 M | $ 13.39 | - | $ 329 M | USA |
 |
Organovo Holdings
ONVO
|
7.73 M | - | -2.3 % | $ 19.4 M | USA |
 |
Exact Sciences Corporation
EXAS
|
889 M | $ 103.37 | - | $ 19.5 B | USA |
 |
OPKO Health
OPK
|
304 M | $ 1.19 | - | $ 826 M | USA |
 |
Bioventus
BVS
|
304 M | $ 8.74 | - | $ 548 M | USA |
 |
DarioHealth Corp.
DRIO
|
18.1 M | $ 10.3 | -4.19 % | $ 292 M | Israel |
 |
Pacific Biosciences of California
PACB
|
141 M | $ 1.52 | - | $ 456 M | USA |
 |
DexCom
DXCM
|
1.29 B | $ 73.08 | - | $ 28.5 B | USA |
 |
PerkinElmer
PKI
|
992 M | - | -0.91 % | $ 14.7 B | USA |
 |
Psychemedics Corporation
PMD
|
7.19 M | - | -1.84 % | $ 15.3 M | USA |
 |
QIAGEN N.V.
QGEN
|
128 M | - | - | $ 10.6 B |  Niderland |
 |
ICON Public Limited Company
ICLR
|
585 M | $ 108.7 | - | $ 8.97 B |  Irlanda |
 |
Quotient Limited
QTNT
|
37.4 M | - | -11.32 % | $ 1.1 M | Schweiz |
 |
Precipio
PRPO
|
9.45 M | $ 24.98 | 1.2 % | $ 32.4 M | USA |
 |
Renalytix AI plc
RNLX
|
19.8 M | - | 5.66 % | $ 22.7 M | Britain |
 |
CareDx, Inc
CDNA
|
108 M | $ 18.8 | - | $ 1 B | USA |
 |
Senseonics Holdings
SENS
|
52.5 M | $ 6.83 | - | $ 285 M | USA |